Is Shree Pacetronix overvalued or undervalued?

As of 7 November 2025, the valuation grade for Shree Pacetronix has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE ratio of 42.67, an EV to EBITDA of 31.48, and a Price to Book Value of 0.63, which suggest that the stock is trading at a lower valuation compared to its earnings and book value. In comparison to its peers, Shree Pacetronix's PE ratio is notably lower than that of Poly Medicure, which stands at 53.67, and Vimta Labs at 47.83, both categorized as very expensive. Additionally, while Shree Pacetronix has a PEG ratio of 11.89, it remains competitive against peers like Blue Jet Health, which has a PEG of 0.29. The company's recent stock performance has significantly outpaced the Sensex, with a year-to-date return of 119.08% compared to the Sensex's 6.50%, reinforcing the narrative of its undervaluation.